2025-05-26-Jefferies-火箭制药公司（RCKT）_FDA对心脏病项目实施临床搁置_损害我们的核心论点_8页_107kb

Rocket Pharmaceuticals (RCKT) Summary

Core Content

Rocket Pharmaceuticals (RCKT) is a late-stage biotechnology company focused on developing genetic medicines for rare diseases. The company has a diversified pipeline with five programs in clinical development and a sixth set to enter the clinic in 2025. Its lead in vivo gene therapy, RP-A501, is in a pivotal Phase II study for Danon disease, which is a key focus of the company's investment thesis.

Key Event

A patient in the pivotal Phase II Danon study experienced a serious adverse event (SAE) of capillary leak syndrome, which led to an acute systemic infection and subsequent death. In response, the FDA placed a clinical hold on May 23, 2025, which may delay the trial and data readout originally expected by mid-2026. This event has introduced uncertainty around the safety and benefit/risk profile of RCKT's gene therapy platform, potentially affecting investor confidence and stock performance.

Impact on the Company

1. Stock Performance: The SAE and FDA clinical hold are expected to lead to significant stock weakness, as the company's core thesis is now under threat.
2. Catalyst Delays: Two key catalysts, including a webinar update in mid-2025 and the Phase II dataset in mid-2026, are now uncertain in timing.
3. Cash Burn and Runway: RCKT has approximately $318M in cash, with a burn rate of $40–50M per quarter. The company estimates this will provide runway until mid-2027, but the clinical hold may increase pressure on cash reserves.
4. Platform Adjustments: RCKT is modifying its immune suppression regimen to reduce complement-mediated activation, a known issue from earlier Phase I trials. The new regimen uses sirolimus instead of tacrolimus and includes more rigorous early monitoring.

Company Overview

RCKT is based in New Jersey and operates as a fully-integrated biotech firm. It is advancing both ex vivo and in vivo gene therapies for rare diseases. Two of its ex vivo programs, RP-L201 (Kresladi) for LAD-I and RP-L102 for Fanconi anemia, are in the regulatory filing stage and could be approved in 2025. These programs may provide non-dilutive capital through PRV vouchers, which could be important as the company navigates the Danon program's challenges.

Valuation and Investment Recommendation

• Price Target: $29.00, representing a +363% increase from the current price of $6.27.
• Rating: Buy.
• Market Cap: $690.3M.
• Valuation Methodology: Includes DCF, EBITDA, P/E, and other financial models.
• Investment Risks: Clinical, regulatory, and commercial risks are noted, with the clinical hold potentially impacting trial timelines and investor sentiment.

Analyst Disclosures

The report includes certifications from analysts, affirming that the views expressed are their own and not influenced by compensation. It also outlines potential conflicts of interest due to Jefferies' business relationships with companies covered in the research.

Legal and Regulatory Notes

The report is subject to various legal disclosures, indicating that it is intended for professional or institutional investors only and may not be suitable for all investors. It is not investment advice and should not be relied upon for making investment decisions without further analysis.

Summary of Key Points

• SAE and Clinical Hold: A patient death due to capillary leak syndrome and acute systemic infection has led to an FDA clinical hold, impacting the Danon program.
• Investor Impact: Uncertainty around trial completion and data readout timelines is increasing, potentially reducing stock upside.
• Cash Management: The company is under pressure to preserve cash, with a burn rate of $40–50M per quarter.
• Platform Adjustments: RCKT is adjusting its immunosuppressive regimen to mitigate safety concerns.
• Investment Thesis: The core thesis is based on the pivotal Phase II study for Danon disease, which is a $1B opportunity.
• Valuation and Risk: The company is rated Buy with a price target of $29.00, but risks include clinical, regulatory, and commercial challenges.

Additional Information

The report includes a chart of rating and price target history, highlighting the frequency of Buy ratings over the past three years. It also provides detailed disclosures regarding the legal jurisdictions and regulations under which the report is issued.